WHITIA launches digital medical X-ray device for screening infectious diseases in developing countries

The World Health Imaging, Telemedicine and Informatics Alliance (WHITIA) today unveiled Remi-d, a new product concept that is intended to provide remote-operated X-ray capabilities for use in screening across areas of the developing world experiencing the Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) co-epidemic, high incidences of Black Lung disease, or outbreaks of other infectious respiratory diseases.

Remi-d is a remote-controlled, self-contained, digital medical X-ray device intended to meet the imaging needs of resource-limited areas such as sub-Saharan Africa, South and Central America and Southeast Asia, where radiologists and technologists are in short supply.

According to the World Health Organization, two-thirds of the world’s population is without access to basic X-ray services – a key component of primary health care delivery. Remi-d is intended to provide advanced capabilities including:

  • Automated patient experience via a computer interface that allows patients to self-manage the multi-lingual capable registration process and retrieve results.
  • Teleradiography through which a remote X-ray technologist can position patients and operate the X-ray equipment.
  • Avatar/Patient Interaction providing a digital representation of the remote technologist in the booth to guide the patient through the X-ray process.
  • Teleradiology that sends Remi-d’s images to remote radiologists for interpretation and diagnosis.

WHITIA partnered with Merge Healthcare and SEDECAL to develop Remi-d with the shared goal of deploying the systems worldwide and providing millions of people with the opportunity to receive life-saving health screenings.

“When Remi-d’s development has been completed and the device has been approved, we hope to make a significant difference in the screening of diseases worldwide,” said Ivy Walker, Chief Executive Officer of WHITIA. “With the support of partners such as Merge Healthcare and others, WHITIA is well-positioned to continue Remi-d’s development and to provide support to sustain the systems when they are ready to be deployed. With ongoing partner and solution development, we believe Remi-d, if approved, could be a leader in remote medical imaging.”

“We are extremely pleased to work with WHITIA on this important concept for better global access to diagnostic imaging,” said Justin Dearborn, Chief Executive Officer of Merge Healthcare. “Over the course of our partnership, we have seen many of the human resource and technical barriers to imaging access experienced by developing communities, and Remi-d is intended to specifically address these very issues. We are proud of the role our technology plays with this new and potentially game changing concept.”

The WHITIA effort is backed by a group of globally recognized business and healthcare leaders including:

  • Newton N. Minow, Chairman of WHITIA, Senior Counsel at Sidley Austin LLP; former Chair of the Federal Communications Commission and of The RAND Corporation; trustee emeritus of the Mayo Clinic
  • Michael W. Ferro, Jr., Chairman and Chief Executive Officer, Merrick Ventures, LLC
  • Max Downham, Executive Director of International College of Surgeons
  • Matthew R. Glucksberg, Professor and Chair of Northwestern University Biomedical Engineering Department
  • David Kelso, Associate Professor of Biomedical Engineering at Northwestern’s McCormick School of Engineering and Applied Sciences and Director of the Center for Innovative Global Health Technologies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough method sheds light on how immune receptors detect infections